Literature DB >> 6352249

Inhibition of insulin degradation by insulin-like growth factors.

R I Misbin, E C Almira, W C Duckworth, T D Mehl.   

Abstract

The effect of insulin-like growth factors (IGF 1 and IGF 2) on insulin degradation was studied with the use of a preparation of insulin protease from rat skeletal muscle. Insulin, IGF 1 and IGF 2 inhibited 125I-insulin degradation by this enzyme. IGF 2 was the most potent inhibitor and IGF 1 was the least potent. These results are similar to what has been reported previously for the insulin-degrading activity in the serum of a diabetic patient who was resistant to sc and im insulin. Insulin protease also degraded 125I-iodo IGF 1 and 125I-iodo IGF 2. 125I-iodo IGF 2 was degraded more rapidly than was 125I-iodo IGF 1. 125I-iodoinsulin was degraded more rapidly than 125I-iodo IGF 2. With all three peptides, immunoprecipitation was a more sensitive measure of degradation than was trichloroacetic acid precipitation. The results suggest that insulin protease may be responsible for the degradation of insulin-like growth factors as well as of insulin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352249     DOI: 10.1210/endo-113-4-1525

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

Review 1.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

Review 2.  Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin.

Authors:  E Malito; R E Hulse; W-J Tang
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

3.  Anion activation site of insulin-degrading enzyme.

Authors:  Nicholas Noinaj; Eun Suk Song; Sonia Bhasin; Benjamin J Alper; Walter K Schmidt; Louis B Hersh; David W Rodgers
Journal:  J Biol Chem       Date:  2011-11-02       Impact factor: 5.157

4.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

Review 5.  Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review.

Authors:  Md Shofiul Azam; Md Wahiduzzaman; Md Reyad-Ul-Ferdous; Md Nahidul Islam; Mukta Roy
Journal:  Pharm Res       Date:  2022-04-04       Impact factor: 4.200

Review 6.  The renal metabolism of insulin.

Authors:  R Rabkin; M P Ryan; W C Duckworth
Journal:  Diabetologia       Date:  1984-09       Impact factor: 10.122

7.  Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.

Authors:  Qing Guo; Marika Manolopoulou; Yao Bian; Alexander B Schilling; Wei-Jen Tang
Journal:  J Mol Biol       Date:  2009-11-05       Impact factor: 5.469

8.  Cellular distribution of insulin-degrading enzyme gene expression. Comparison with insulin and insulin-like growth factor receptors.

Authors:  C A Bondy; J Zhou; E Chin; R R Reinhardt; L Ding; R A Roth
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  Degradation of relaxin family peptides by insulin-degrading enzyme.

Authors:  Robert G Bennett; Dean G Heimann; Frederick G Hamel
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

Review 10.  Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Authors:  Carlos M González-Casimiro; Beatriz Merino; Elena Casanueva-Álvarez; Tamara Postigo-Casado; Patricia Cámara-Torres; Cristina M Fernández-Díaz; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo
Journal:  Biomedicines       Date:  2021-01-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.